Short description
GT Biopharma specializes in the research and development of therapeutic products used primarily for the treatment of cancer.
Description
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immunology therapeutic products based on our proprietary Trispecific Killer Engagers (TriKE™) target-directed Natural Killer (NK) cell engager platform. The TriKE™ NK protein biologic platform is designed to harness and amplify the body’s native immune system for hope for patients with cancer and infectious diseases.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Westlake Village, California, United States, North America
Founded on
January 1, 1965
Exited on
February 11, 2021
Went public on
February 11, 2021
Stock symbol
GTBP
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noway Youcantaccess
Sign in for full access
Founders
Kathleen E. Clarence-Smith, STEVEN WELDON